We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.29 | 0.66% | 43.99 | 44.33 | 43.685 | 43.93 | 12,104,157 | 01:00:00 |
From May 2019 to May 2024
By Michael Calia
Alder Biopharmaceuticals Inc. filed for an initial public offering of up to $115 million in common stock, as the company looks to fund product development.
The company said it seeks to commercialize therapeutic antibodies. Its pipeline includes two internally discovered antibodies--one wholly owned, one shared in a partnership with Bristol-Myers Squibb--as well as preclinical programs.
Alder said it intends to use the proceeds of the IPO to fund its continuing clinical program for its wholly owned ALD403 treatment, preclinical development and general corporate purposes.
Credit Suisse and Leerink Partners are running the offering, according to the filing.
Alder posted a net loss of $20.6 million in 2013 compared with $17.8 million in 2012, as total operating expenses increased.
The company intends to list its share on the Nasdaq under the symbol ALDR.
Write to Michael Calia at michael.calia@wsj.com
Access Investor Kit for Bristol-Myers Squibb Co.
Visit http://www.companyspotlight.com/partner?cp_code=A591&isin=US1101221083
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
